Loading clinical trials...
Loading clinical trials...
The purpose of this study was to assess the incidence of human anti-chimeric antibody (HACA) in high-risk neuroblastoma patients treated with Unituxin combination therapy.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
United Therapeutics
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT06540963 · Neuroblastoma
NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT06721689 · Refractory Solid Tumors, Relapsed Solid Tumors, and more
University Of Alabama At Birmingham
Birmingham, Alabama
Arkansas Children's Hospital
Little Rock, Arkansas
Children's Hospital Los Angeles
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions